Bogle Investment Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Bogle Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-46,042	Closed	-$96K	–	480
2016 Q3	$96K	Sell	46,042 -52,444	-53%	-$104K	0.01%	342
2016 Q2	$158K	Sell	98,486 -3,600	-4%	-$6.91K	0.01%	368
2016 Q1	$99K	Sell	102,086 -59,267	-37%	-$57.8K	0.01%	367
2015 Q4	$195K	Buy	161,353 +137,388	+573%	+$441K	0.01%	347
2015 Q3	$178K	Buy	+23,965	New	+$183K	0.01%	346
2015 Q1	–	Sell	-17,512	Closed	-$174K	–	491
2014 Q4	$174K	Sell	17,512 -757,795	-98%	-$6.46M	0.01%	335
2014 Q3	$7.67M	Buy	+775,307	New	+$11.5M	0.5%	84

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Bogle Investment Management's RPRX Position: Q4 2016 in Review

Bogle Investment Management sold out of Repros Therapeutics Inc. (RPRX) in Q4 2016, closing a stake of 46,042 shares — an estimated $96K sold.

Bogle Investment Management first reported a position in RPRX in Q3 2014 and held it in 7 quarters. The position peaked at $7.67M in Q3 2014. 43 funds tracked by Wall St. Rank hold RPRX as of Q4 2016.

Bogle Investment Management reported no remaining Repros Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
Bogle Investment Management sold 46,042 Repros Therapeutics Inc. shares in Q4 2016, an estimated $96K.
Bogle Investment Management first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 7 quarters.
Bogle Investment Management's Repros Therapeutics Inc. position peaked at $7.67M in Q3 2014.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2016.

Based on Bogle Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.